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Abstract
X-linked hypophosphatemia (XLH) is the most frequent form of inherited rickets in humans
caused by mutations in the phosphate-regulating gene with homologies to endopeptidases
on the X-chromosome (PHEX). Hypmice, a murine homologue of XLH, are characterized
by hypophosphatemia, inappropriately low serum vitamin D levels, increased serum fibro-
blast growth factor-23 (Fgf23), and osteomalacia. Although Fgf23 is known to be responsi-
ble for hypophosphatemia and reduced vitamin D hormone levels in Hypmice, its putative
role as an auto-/paracrine osteomalacia-causing factor has not been explored. We recently
reported that Fgf23 is a suppressor of tissue nonspecific alkaline phosphatase (Tnap) tran-
scription via FGF receptor-3 (FGFR3) signaling, leading to inhibition of mineralization
through accumulation of the TNAP substrate pyrophosphate. Here, we report that the pyro-
phosphate concentration is increased in Hyp bones, and that Tnap expression is decreased
in Hyp-derived osteocyte-like cells but not in Hyp-derived osteoblasts ex vivo and in vitro. In
situ mRNA expression profiling in bone cryosections revealed a ~70-fold up-regulation of
Fgfr3mRNA in osteocytes versus osteoblasts of Hypmice. In addition, we show that block-
ing of increased Fgf23-FGFR3 signaling with anti-Fgf23 antibodies or an FGFR3 inhibitor
partially restored the suppression of Tnap expression, phosphate production, and minerali-
zation, and decreased pyrophosphate concentration in Hyp-derived osteocyte-like cells in
vitro. In vivo, bone-specific deletion of Fgf23 in Hypmice rescued the suppressed TNAP
activity in osteocytes of Hypmice. Moreover, treatment of wild-type osteoblasts or mice with
recombinant FGF23 suppressed TnapmRNA expression and increased pyrophosphate
concentrations in the culture medium and in bone, respectively. In conclusion, we found
that the cell autonomous increase in Fgf23 secretion in Hyp osteocytes drives the accumu-
lation of pyrophosphate through auto-/paracrine suppression of TNAP. Hence, we have
identified a novel mechanism contributing to the mineralization defect in Hypmice.
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Author Summary
X-linked hypophosphatemia (XLH) is the most frequent form of inherited rickets in
humans. A mouse model of XLH, known asHyp, is characterized by exceptionally low
serum phosphate and vitamin D levels, increased serum levels of the hormone fibroblast
growth factor-23 (Fgf23), and impaired bone mineralization. Fgf23 is secreted from two
classes of bone cells known as osteoblasts and osteocytes. Fgf23 increases urinary phosphate
excretion and suppresses vitamin D hormone production in the kidney. Although Fgf23 is
known to be responsible for lower blood phosphate and vitamin D hormone levels inHyp
mice, its putative role as a signaling factor causing impaired mineralization has not been
explored. We recently reported that Fgf23 is a suppressor of tissue nonspecific alkaline
phosphatase (Tnap) gene expression via FGF receptor-3 (FGFR3) signaling in osteoblasts,
leading to inhibition of mineralization through accumulation of the TNAP substrate pyro-
phosphate. Pyrophosphate is a potent inhibitor of mineralization. Using a combination of
cell culture and animal models, we report that the increase in osteocyte Fgf23 secretion of
Hypmice leads to FGFR3-mediated suppression of TNAP with subsequent accumulation
of pyrophosphate. Hence, we have identified a novel signaling mechanism by which exces-
sive osteocytic secretion of Fgf23 contributes to the mineralization defect inHypmice.
Introduction
X-linked hypophosphatemia (XLH) is the most frequent form of inherited rickets in humans.
XLH is caused by inactivating mutations in the phosphate-regulating gene with homologies to
endopeptidases on the X-chromosome (PHEX) [1–3]. Similarly, a loss-of-function deletion in
Phex, the murine homologue of PHEX, leads to an XLH-like phenotype in Hypmice, a well-
known animal model for XLH [4–6]. PHEX/Phex is predominantly expressed in bone and
teeth and at lower levels in muscle, skin, brain, and lungs [7,8]. Both XLH patients and Hyp
mice are characterized by hypophosphatemia, impaired bone mineralization, inappropriately
low serum vitamin D hormone (1,25(OH)2D3), and increased circulating intact fibroblast
growth factor-23 (FGF23) [9–11]. FGF23 is a phosphaturic hormone, mainly produced by
osteoblasts and osteocytes in response to increased extracellular phosphate and circulating 1,25
(OH)2D3 [12]. In renal proximal tubules, FGF23 suppresses the membrane expression of the
type II sodium-phosphate cotransporters Npt2a and Npt2c, which are necessary for the urinary
reabsorption of phosphate [13]. In addition, FGF23 suppresses the renal proximal tubular
expression of 1α-hydroxylase [14], the key enzyme responsible for vitamin D hormone pro-
duction. Fgf23 requires the obligatory coreceptor α-Klotho (Klotho) to bind to the ubiquitously
expressed fibroblast growth factor receptor 1c (FGFR1c) [15,16]. Hence, the hormonal actions
of Fgf23 are restricted, at least at physiological concentrations, to tissues expressing Klotho
such as proximal and distal tubules in the kidney, parathyroid gland, choroid plexus in the
brain, and sinoatrial node in the heart [13,17].
The molecular mechanisms why loss of PHEX/Phex function leads to increased FGF23
secretion in osteoblasts and osteocytes are still incompletely understood. PHEX is an ectoen-
zyme thought to be involved in the proteolytic processing of extracellular matrix (ECM) pro-
teins. Earlier studies in Hypmice revealed aberrant processing of SIBLING (Small Integrin-
Binding Ligand, N-linked Glycoprotein) proteins such as matrix extracellular phosphoglyco-
protein (MEPE) [18], causing accumulation of acidic serine- and aspartate-rich MEPE-associ-
ated motif (ASARM) peptides. ASARM peptides are potent inhibitors of mineralization, and
are thought to be at least partially responsible for the mineralization defect observed in Hyp
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mice [19]. Another substrate of PHEX is the ECM protein osteopontin (OPN), a well-known
mineralization inhibitor that binds to hydroxyapatite (HA) crystals and blocks the deposition
of HA onto ECM [20]. In addition to ASARM peptides, OPN was shown to be increased in
bones ofHypmice [21]. Because the mineralization defect present in Dentin matrix protein-1
(Dmp-1)-deficient mice also leads to overexpression of Fgf23 [22], it is currently thought that
osteocytes respond to impaired mineralization by increased Fgf23 secretion. It is interesting to
note in this context that ablation of Fgfr1 in bone partially rescues the excessive Fgf23 secretion
inHypmice, suggesting that Fgfr1-mediated signaling may somehow be involved in the mech-
anism how osteocytes sense mineralization in the surrounding matrix [23]. In addition, long-
term inhibition of FGFR by a pan-FGFR inhibitor inHyp and Dmp-1-deficient mice leads to
normalization of serum phosphate and calcium and improves mineralization [24]. Besides dis-
turbed mineralization, defective phosphate sensing in osteoblasts has also been implicated to
play a role in the augmented Fgf23 secretion in Hypmice [25].
Although the exact mechanism driving Fgf23 secretion in Phex and Dmp-1-deficient models
has remained elusive thus far, several lines of evidence suggest that increased circulating Fgf23
is a major pathogenetic factor in XLH patients and Hypmice, leading to hypophosphatemia
and subsequently impaired bone mineralization. Firstly, extraskeletal overexpression of FGF23
also causes hypophosphatemia and osteomalacia [26,27]. Secondly, ablation of Fgf23 inHyp
mice recapitulates the Fgf23-null phenotype [28,29]. Thirdly, treatment ofHypmice with anti-
Fgf23 antibodies normalizes serum phosphate and vitamin D hormone levels, decreases osteoid
volume, and improves bone mineralization [9,15,24]. All these findings suggest that excessive
Fgf23 secretion is the major driving force behind the Hyp phenotype.
However, because osteoblasts isolated fromHypmice fail to mineralize in a normal fashion
in vitro [30], and dietary phosphate supplementation attempting to correct hypophosphatemia
did not rescue the osteomalacia inHypmice [31], it is likely that the mineralization defect in
Hypmice has at least two components, namely systemic hypophosphatemia plus independent
alterations in the ECM [32]. The relative contribution of local accumulation of ASARM pep-
tides and of OPN in the ECM versus the endocrine phosphaturic effect of Fgf23 to the osteo-
malacia observed inHypmice is currently unclear.
We recently discovered that FGF23 suppresses tissue nonspecific alkaline phosphatase
(TNAP) transcription and leads to decreased local inorganic phosphate (Pi) production as well
as accumulation of pyrophosphate (PPi) by a Klotho-independent, FGFR3-mediated signaling
axis in osteoblasts [33]. PPi is another well-known inhibitor of mineralization produced by
osteoblasts and osteocytes. Increased levels of PPi in the ECM are known to impair the miner-
alization process by binding to HA crystals [34–36]. Conversely, absence of PPi in the ECM
either via genetic ablation of its intracellular-to-extracellular transporter progressive ankylosis
(ANK) [37] or ablation of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) [38],
an enzyme which produces PPi from ATP, results in hypermineralization of bones. Increased
levels of PPi in the ECM can be a consequence of two different mechanisms, either increased
production and transportation of PPi to the ECM, or decreased hydrolysis of PPi by TNAP,
leading to accumulation of PPi in the ECM.
Based on our recent finding that Fgf23 is a regulator of Tnap transcription, we hypothesized
that excessive Fgf23 secretion inHyp osteocytes could locally contribute to defective minerali-
zation by suppressing TNAP and increasing PPi concentrations. Here, we report that the PPi
concentration is indeed increased inHyp bones, and that Tnap expression is decreased in Hyp-
derived osteocyte-like cells ex vivo and in vitro. In addition, we show that blocking of increased
Fgf23-FGFR3 signaling in Hyp-derived osteocyte-like cells partially restores the suppression of
TNAP expression, phosphate production, and mineralization in vitro. Thus, we have identified
a novel mechanism contributing to the defective mineralization inHypmice.
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Results
PPi Concentration Is Increased in Bones of HypMice
It is well known thatHypmice are characterized by hypophosphatemia, hypocalcemia, impaired
bone mineralization, and increased serum Fgf23 [9]. This was confirmed in our study. Three-
month-old maleHypmice used in our experiments were hypophosphatemic and hypocalcemic,
exhibited elevated serum alkaline phosphatase (ALP) activity and increased serum intact Fgf23
(Fig 1A) and showed impaired bone mineralization as evidenced by widened osteoid seams and
enlarged osteocyte lacunae in histological bone sections (Fig 1B). Since it was previously
reported that OPN protein expression is increased inHypmice [21], we quantified OPN protein
expression in femur extracts from wild-type (WT) andHypmice by western blotting. As shown
in Fig 1C, OPN protein expression was higher inHyp femur extracts compared to WTmice.
Immunohistochemistry confirmed increased OPN protein expression inHyp compared toWT
bones (Fig 1C, lower panel). According to our hypothesis, the concentration of PPi should be
increased inHyp bones. To initially test whether this hypothesis may be worth pursuing, we
quantified the amount of PPi in WT andHypmice femur extracts. As shown in Fig 1D, the PPi
concentration inHyp bones was indeed higher compared to WT bones.
Osteocyte-Rich Cell Fractions Isolated from Hyp Femurs Show
Increased mRNA Expression of PPi Regulating Genes and Decreased
TnapmRNA Expression Ex Vivo
Our hypothesis predicts that increased Fgf23 secretion in bone cells fromHypmice would sup-
press TNAP and would subsequently lead to accumulation of PPi. However, in contrast to our
hypothesis, serum ALP in Hyp was actually higher compared to WT mice (Fig 1A). However,
we reasoned that the inhibitory effect of Fgf23 on TNAP might be cell-specific in bone and
might only occur in osteocytes where the Fgf23 concentrations in the extracellular fluid are
probably highest. To investigate a potential cell-specific effect of Fgf23 on osteoblasts and oste-
ocytes, we isolated osteoblast- and osteocyte-rich fractions from femurs of WT andHypmice,
using a sequential digestion technique [39]. To confirm the successful isolation of osteoblasts
and osteocytes, we analyzed the mRNA abundance of the osteoblast-specific marker osteocal-
cin (Ocn) [40], and of the osteocyte-specific marker sclerostin (Sost) [41]. Fractions (F) 1 and 2
were discarded because of the high contamination with other cell types. In both WT and Hyp
mice, F-3 showed higher levels of OcnmRNA expression compared to the other fractions (Fig
2A), suggesting that this was an osteoblast-rich fraction. Conversely, SostmRNA expression
was low in F-3, F-4, and F-5, and increased 5- to 40-fold in F-6/7 and F-8/9, respectively (Fig
2A). Based upon these results we considered fractions 3–5 as osteoblast-rich, and F-6/7 and F-
8/9 as osteocyte-rich in both WT andHyp femurs (Fig 2A).
Analysis of gene expression in osteoblast-rich fractions revealed lower mRNA expression of
Ank and Enpp1 and ~50-fold higher Tnap expression in Hyp- versus WT-derived F-3 (Fig 2B).
The most pronounced differences between WT andHypmice were observed in F-3. Interest-
ingly, Fgf23 and OpnmRNA expression remained unchanged between the genotypes in all
three fractions, confirming an earlier report that osteoblastic Fgf23 production is not different
between WT and Hypmice [39]. The mRNA expression of Fgfr1 and Fgfr3 was lower in Hyp-
versus WT-derived F-3 and/or F-5. In contrast, the mRNA abundance of Ank, Enpp1, Opn,
Fgf23, Fgfr1, and Fgfr3 was distinctly increased inHyp-derived osteocyte-rich fractions F-6/7
and/or F-8/9 (Fig 2C). Most interestingly, TnapmRNA abundance was decreased by 80%–90%
inHyp-derived osteocyte-rich fractions F-6/7 and F-8/9, relative to WT-derived osteocytes (Fig
2C). In accordance with the mRNA data, western blotting analysis of the pooled protein
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samples showed unchanged TNAP protein abundance in osteoblast-rich fractions F-3/4/5 but
lower TNAP protein abundance in osteocyte-rich fractions F-6/7/8/9 isolated fromHypmice,
relative to WT controls (Fig 2D).
Collectively, these results corroborate the notion that osteocytes are the major source of the
increased circulating Fgf23 levels in Hypmice. Furthermore, our data show that there is not
only increased OPN expression, but also increased mRNA expression of PPi-regulating factors
such as Ank and Enpp1 inHyp-derived osteocytes. Collectively, the observed changes in gene
Fig 1. PPi concentration is increased in femurs of Hypmice. (A) Serum calcium, phosphate, ALP activity, and intact Fgf23 in 3-mo-old male WT andHyp
mice. (B) Von Kossa/McNeal staining of 3-μm-thick undecalcified plastic sections of distal femurs from 3-mo-old male WT andHypmice and quantification of
mean area of osteocytic lacunae. (C)Quantification of OPN protein expression by western blotting of proteins isolated from femurs (upper panels) and
immunohistochemical staining of OPN protein expression in femoral cortical bone (lower panels) in 3-mo-old male WT andHypmice. (D) PPi concentration
in extracts of whole femurs from 3-mo-old male WT andHypmice. Each data point is the mean ± standard deviation (SD) of four mice. Individual values are
given in S1 Data. *, p < 0.05 versusWT.
doi:10.1371/journal.pbio.1002427.g001
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Fig 2. Osteocyte-rich cell fractions isolated fromHyp femurs show increasedmRNA expression of PPi-regulating genes and decreasedmRNA
expression of Tnap ex vivo. (A)mRNA abundance of the osteoblast-specific geneOcn and of the osteocyte-specific gene Sost in total RNA isolated from
cell fractions harvested by sequential digestion from femurs of 3-mo-old male WT andHypmice. (B–C) Ank, Enpp1, Opn, Fgf23, Tnap, Fgfr1, and Fgfr3
mRNA abundance in total RNA isolated from osteoblast-rich fractions F-3 to F-5 (B) and from osteocyte-rich fractions F-6/7 to F-8/9 (C) harvested by
sequential digestion from femurs of 3-mo-old male WT andHypmice. (D) TNAP protein expression in pooled osteoblast- and osteocyte-rich fractions
harvested by sequential digestion from femurs of 3-mo-old male WT andHypmice. Each data point is the mean ± SD of four samples from four different mice.
Individual values are given in S1 Data. *, p < 0.05 versus F-3 in A; *, p < 0.05 versusWT in B–C; *, p < 0.05 versusWT F-3/4/5 in D.
doi:10.1371/journal.pbio.1002427.g002
Auto-/paracrine Role of Fgf23 in Hyp-induced Osteomalacia
PLOS Biology | DOI:10.1371/journal.pbio.1002427 April 1, 2016 6 / 24
expression of Ank, Enpp1, and Tnap inHyp-derived osteocyte-rich cell fractions are able to
explain the accumulation of PPi in the ECM ofHyp bones.
Osteocyte-Like Cells Isolated from HypMice Show Cell Autonomous
Suppression of TNAPmRNA Expression and of Phosphate Production
To further examine whether osteoblasts and osteocytes isolated fromHypmice differentially
express PPi-regulating genes and Tnap in a cell autonomous fashion, we moved from the
above mentioned ex vivo approach to an in vitro model. To this end, we isolated calvarial oste-
oblasts from newborn WT and Hypmice, and differentiated the cells up to 22 d. At day 12,
only little mineralized nodule formation was observed, and cells expressed maximum levels of
OcnmRNA, whereas at day 22, more mineralized nodules were formed and the mRNA expres-
sion of Sost was highest (Fig 3A). Therefore, we considered cells harvested at day 12 as differen-
tiated osteoblasts and cells harvested at day 22 as osteocyte-like cells.
mRNA expression analysis at day 12 revealed no significant differences in Ank, Enpp1, and
Opn expression betweenWT osteoblasts andHyp osteoblasts (Fig 3B). Fgfr1mRNA abundance
was up-regulated, whereas Fgfr3mRNA expression was lower inHyp versus WT osteoblasts (Fig
3B). Fgf23mRNA abundance was higher inHyp compared toWT osteoblasts already at day 12
(Fig 3B). We further analyzed if this increase in Fgf23mRNA expression led to increased Fgf23
secretion in the cell culture medium. We found ~60-fold higher concentrations of intact Fgf23
in the culture medium ofHyp osteoblasts (Fig 3B). Despite increased Fgf23mRNA expression
and secretion, TnapmRNA expression was increased inHyp compared withWT osteoblasts
(Fig 3B). Assessment of TNAP protein expression using western blotting analysis and of TNAP
enzyme activity using BCIP/NBT staining showed similar levels of protein expression and activ-
ity inWT andHyp osteoblasts at day 12 (Fig 3B). It is well known that TNAP is responsible for
Pi production in vitro during differentiation by cleaving β–glycerophosphate, a component of
the differentiation medium [42]. Therefore, we assessed Pi concentration in the culture medium
as readout for TNAP enzyme activity. Pi concentration in the medium ofHyp osteoblasts was
lower than that of WT osteoblasts (Fig 3B). We currently don’t have a good explanation for the
discrepancy between TnapmRNA expression and enzyme activity at the 12-day time point in
Hyp-derived osteoblasts. As another readout for TNAP enzyme activity, we analyzed PPi con-
centration in the cell culture medium. However, no significant changes in PPi concentration
were observed between cell culture medium fromWT andHyp osteoblasts at day 12 (Fig 3B).
In analogy to the osteocyte-rich fractions isolated fromHyp femurs, mRNA abundance of
Ank, Enpp1, Opn, Fgf23, and Fgfr3 was increased, whereas mRNA expression of Tnap was
decreased, in Hyp compared to WT osteocyte-like cells differentiated for 22 d (Fig 3C). BCIP/
NBT staining and western blotting analysis confirmed the decreased TNAP protein expression
and activity inHyp versus WT osteocyte-like cells (Fig 3C). In accordance with decreased Tnap
expression, Pi concentration was lower and PPi concentration was higher in the cell culture
medium fromHyp versus WT osteocyte-like cells (Fig 3C). Similar to our findings in osteo-
blast-like cells, intact Fgf23 in the culture medium was increased inHyp-derived osteocyte-like
cells (Fig 3C). Taken together, our data suggest that the up-regulation in Ank, Enpp1, and Opn,
as well as the downregulation in TnapmRNA and protein expression are cell autonomous
effects inHyp osteocyte-like cells.
Suppression of TNAP Activity and Up-regulation of Fgfr3mRNA
Expression in HypOsteocytes In Vivo
To validate our ex vivo and in vitro finding that TNAP is suppressed inHyp-derived osteocyte-
like cells, we examined TNAP enzyme activity in osteoblasts and osteocytes in sections of
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Fig 3. Osteocyte-like cells isolated fromHypmice display decreased TnapmRNA expression together with PPi accumulation in vitro. (A)mRNA
abundance of the osteoblast-specific geneOcn and of the osteocyte-specific gene Sost in calvarial cells isolated from newbornWT andHypmice and
differentiated for 0–22 d (D0–D22). (B–C)mRNA abundance of Ank, Enpp1,Opn, Fgf23, Tnap, Fgfr1, and Fgfr3 as well as concentration of Pi, PPi, and intact
Fgf23 in cell culture supernatant, percentage NBT/BCIP-stained area, and TNAP protein expression in calvarial cells isolated from newbornWT andHyp
mice and differentiated for 12 d (differentiated osteoblasts) (B) or 22 d (osteocyte-like cells) (C). Each data point is the mean ± SD of triplicates from four
different animals. Individual values are given in S1 Data. *, p < 0.05 versus D0 in A; *, p < 0.05 versusWT in B and C.
doi:10.1371/journal.pbio.1002427.g003
Auto-/paracrine Role of Fgf23 in Hyp-induced Osteomalacia
PLOS Biology | DOI:10.1371/journal.pbio.1002427 April 1, 2016 8 / 24
femurs fromWT andHypmice. As shown in Fig 4A, TNAP enzyme activity was profoundly
suppressed in osteocytes, but not in osteoblasts, of Hyp compared with WTmice, corroborat-
ing the ex vivo and in vitro data.
A puzzling finding in our in vitro experiments with calvarial cells was that the up-regulated
Fgf23 secretion observed in both osteoblast- and osteocyte-like cells from Hypmice sup-
pressed TnapmRNA and protein abundance only in osteocyte-like cells but not in osteoblasts.
To rule out that this finding was due to the calvarial origin of the cells, we isolated osteoblasts
from femurs of newborn WT and Hypmice and differentiated them for 12 and 22 d. Similar
to calvarial cells, osteocalcin expression was higher at day 12, whereas Sost expression was
higher at day 22 compared to day 12, consistent with a differentiated osteoblast-like pheno-
type at day 12 and an osteocyte-like phenotype at day 22 (S1A Fig). At day 12, femoral osteo-
blasts isolated from Hypmice showed increased TnapmRNA expression, decreased
phosphate production, but unchanged BCIP/NBT staining relative to WT cells (S1B and S1C
Fig). After 22 d of differentiation, TnapmRNA abundance, phosphate production, and BCIP/
NBT staining were decreased in Hyp versus WT cells (S1B and S1C Fig). Fgf23mRNA abun-
dance was increased in Hyp versus WT cells at day 12 and 22 (S1B Fig). To test the differential
sensitivity of calvarial versus femoral osteoblasts and osteocytes to recombinant FGF23
(rFGF23), we treated WT and osteoblasts and osteocyte-like cells with different doses of
rFGF23, and monitored TnapmRNA expression. The rFGF23-induced suppression of Tnap
mRNA expression was generally similar in calvarial versus femoral osteoblasts and osteocyte-
like cells fromWT and Hypmice (S2 Fig). However, in line with a lower sensitivity of Hyp-
derived osteoblasts, higher concentrations of rFGF23 were needed to suppress TnapmRNA in
Hyp femoral and calvarial osteoblasts, relative to osteocytes (S2 Fig). Hence, the differences in
TNAP expression and the response to pharmacological treatment with rFGF23 between oste-
oblasts and osteocyte-like cells isolated from Hypmice were similar in cells derived from cal-
varial and femoral origin.
We previously reported that FGF23 inhibits Tnap transcription via FGFR3 [33]. The
abovementioned increase in Fgfr3mRNA in Hyp osteocyte-rich fractions and osteocyte-like
cells relative to WT cells would be consistent with the notion that the up-regulation of
FGFR3 during osteocytic differentiation is the pivotal process making Hyp osteocytes more
responsive to the suppressive effect of Fgf23 on Tnap transcription. To confirm the up-regu-
lation of Fgfr3mRNA during osteocytic differentiation in vivo, we performed in situ mRNA
expression analysis in frozen femur sections, employing laser capture microdissection
(LCM), a technique which we recently developed [43]. We found that Fgf23mRNA abun-
dance was ~3-fold higher in WT osteocytes than in WT osteoblasts (Fig 4B). Relative to WT
osteoblasts, Fgf23mRNA expression was ~6–7-fold higher in Hyp osteoblasts and
osteocytes (Fig 4B). In accordance with our in vitro and ex vivo data, TnapmRNA expres-
sion was increased in Hyp osteoblasts, but suppressed in Hyp osteocytes, relative to WT oste-
oblasts and osteocytes, respectively (Fig 4B). Fgfr1mRNA expression was higher in
osteoblasts and osteocytes of Hypmice, relative to WT controls (Fig 4B). Notably, Fgfr3
mRNA abundance was ~5-fold higher in WT osteocytes than in WT osteoblasts, whereas
Fgfr3mRNA expression was suppressed in Hyp versus WT osteoblasts, but profoundly up-
regulated in Hyp osteocytes (Fig 4B). Hyp osteocytes showed ~70-fold higher Fgfr3mRNA
abundance than Hyp osteoblasts. Taken together, these findings support the notion that the
distinct up-regulation in Fgfr3mRNA expression during osteocytic differentiation especially
in Hypmice is permissive to the Fgf23-mediated suppression of Tnap transcription in vitro
and in vivo.
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Fig 4. Decreased TNAP enzyme activity and up-regulated expression of Fgfr3mRNA inHyp osteocytes in vivo. (A) Histochemical TNAP staining in
undecalcified sections of distal femurs fromWT andHypmice and quantification of relative fluorescence. Top panels for each genotype show endocortical
bone surface, bottom panels cortical bone. Each data point is the mean ± SD of at least four mice. (B) In situ mRNA expression profiling of osteoblasts and
osteocytes harvested by laser capture microdissection (LCM) in 4-μm-thick distal femoral cryosections. Each data point is the mean ± SD of three mice.
Individual values are given in S1 Data. *, p < 0.05 versusWT osteocytes in A; *, p < 0.05 versusWT osteoblasts, #, p < 0.05 versusWT osteocytes in B.
doi:10.1371/journal.pbio.1002427.g004
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Blocking of Fgf23—FGFR3 Signaling Increases TNAPmRNA
Expression and Pi Production in HypOsteocyte-Like Cells In Vitro
Next, we examined whether the changes in the mRNA expression of PPi-regulating genes in
Hyp osteocyte-like cells are causatively linked to increased Fgf23 secretion. To this end, we iso-
lated osteoblasts from newborn Hyp and WTmice, and treated osteocyte-like cells differenti-
ated for 22 d with either neutralizing anti-FGF23 antibody (FGF23 AB) or an FGFR3 inhibitor
for 24 h. In analogy to the experiments shown in Fig 3,Hyp osteocyte-like cells expressed dis-
tinctly lower TnapmRNA, and showed lower Pi but higher PPi concentrations in cell culture
medium, relative to WT cells (Fig 5A and 5B). With the exception of an up-regulation in Opn
mRNA abundance, treatment of osteocyte-like cells with either FGFR3 inhibitor or FGF23 AB
did not have significant effects in WT cells, but increased Tnap and Opn, and lowered Ank and
Enpp1mRNA expression in Hyp osteocyte-like cells, relative to vehicle-treated cells (Fig 5A
and 5B). However, both treatments did not restore TnapmRNA expression inHyp osteocyte-
like cells to WT control levels. In concordance with the increased TnapmRNA expression after
inhibition of Fgf23 signaling, treatment of Hyp osteocyte-like cells with either FGFR3 inhibitor
or FGF23 AB increased Pi and decreased PPi concentrations in the cell culture medium (Fig
5A and 5B).
Finally, to determine if longer term inhibition of Fgf23 signaling in Hyp osteocyte-like cells
translates into a more complete correction of TNAP activity and PPi levels, we treated osteo-
cyte-like cells with either FGFR3 inhibitor or FGF23 AB for 96 h and subsequently assessed
PPi concentration and TNAP enzyme activity, using NBT/BCIP staining for the latter. As
shown in Fig 5C, both treatments did not alter ALP staining or PPi concentration in WT osteo-
cyte-like cells. However, treatment with either FGFR3 inhibitor or FGF23 AB increased ALP
staining inHyp osteocyte-like cells compared to vehicle-treated cells. The increase in TNAP
activity was accompanied by a profound increase in Pi concentration and normalization of PPi
levels in cell culture medium fromHyp osteocyte-like cells treated with either FGFR3 inhibitor
or FGF23 AB (Fig 5C).
Taken together, our data provide evidence that increased Fgf23-FGFR3 signaling inhibits
TNAP activity in Hyp osteocytes, causing PPi accumulation which in turn contributes to the
mineralization defect observed in Hypmice. However, inhibition of Fgf23 signaling did not
completely normalize TNAP mRNA expression and enzyme activity, suggesting that other,
still unknown factors are involved in the regulation of TNAP in Hyp osteocytes. Of note, inhi-
bition of Fgf23 signaling increased phosphate concentrations in the cell culture medium
beyond the levels found in WT osteocyte-like cells (Fig 5C). This finding may suggest that the
increased phosphate production after inhibition of Fgf23 signaling could not be adequately
used for mineralization inHyp osteocyte-like cells due to the presence of additional inhibitors
of mineralization, most likely OPN and ASARM peptides due to Phex deficiency.
rFGF23 Suppresses TnapmRNA Expression and Increases PPi in Wild-
Type Osteocyte-Like Cells In Vitro and Bones of Wild-Type Mice In Vivo
Hyp osteocyte-like cells are not only characterized by suppressed Tnap expression but also by
increased abundance of genes associated with PPi production such as Enpp1 and Ank. To
exclude the role of altered PPi production after inhibition of Fgf23 signaling inHyp osteocyte-
like cells, we treated WT osteocyte-like cells with rFGF23. We previously showed that treat-
ment of WT osteoblasts with rFGF23 does not alter the expression of Enpp1 and Ank [33].
Treatment of WT osteoblasts with rFGF23 suppressed TnapmRNA expression and increased
PPi concentrations in the culture medium, independent of changes in expression of Enpp1 or
Ank (Fig 6A).
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Fig 5. Inhibition of Fgf23-FGFR3 signaling increases TNAP expression and lowers PPi concentration inHyp-derived osteocyte-like cells. (A–B)
Ank, Enpp1, Opn and TnapmRNA abundance as well as Pi and PPi concentration in cell culture supernatant of calvarial osteocyte-like cells differentiated for
22 d and treated for 24 h with a FGFR3 inhibitor (A) or anti-FGF23 antibody (FGF23 AB) (B). (C) Phosphate and PPi concentration in cell culture supernatant
as well as percent NBT/BCIP-stained area in cultures of calvarial osteocyte-like cells differentiated for 22 d, and treated daily over 4 d with a FGFR3 inhibitor
or FGF23 AB. Each data point is the mean ± SD of four experimental samples. Individual values are given in S1 Data. *, p < 0.05 versus vehicle-treated WT
cells, #, p < 0.05 versus vehicle-treated Hyp cells.
doi:10.1371/journal.pbio.1002427.g005
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To further validate the link between Fgf23, TNAP, and PPi in vivo, we treated WTmice
with rFGF23. A 5-d treatment with rFGF23 suppressed TnapmRNA expression (Fig 6B) and
significantly increased PPi concentrations in bones of WT mice (Fig 6B). In line with our in
vitro data, rFGF23 treatment did not alter mRNA levels of Ank and Enpp1 in bones. Taken
together, these data corroborate the notion that extracellular FGF23 is independently associ-
ated with PPi levels in bone through its suppressive effect on TNAP.
Osteoblast Lineage Specific Deletion of Fgf23 Rescues the Suppression
of TNAP Activity in Osteocytes of HypMice
Finally, to test whether excessive secretion of Fgf23 is responsible for the decreased Tnap
expression and PPi accumulation inHyp bones in vivo, we analyzed bones fromHypmice in
which Fgf23 was specifically deleted in cells of the osteoblastic lineage. To this end, we used a
novel mouse model (Fgf23Δ/flox/Col2.3cre+) carrying a germline-deleted Fgf23 allele together
with a floxed Fgf23 allele. Fgf23Δ/flox mice were mated with type 1 collagen 2.3 kb promoter-cre
mice, resulting in deletion of Fgf23 in the osteoblast lineage [44]. Fgf23Δ/flox/Col2.3cre+ mice
were mated withHypmice to obtainHyp/Fgf23Δ/flox/Col2.3cre+ mice, aHypmouse model with
conditional deletion of Fgf23 in osteoblasts and osteocytes. Analysis of TNAP enzyme activity
in femur sections of 3-mo-old WT, Hyp, andHyp/Fgf23Δ/flox/Col2.3cre+ mice showed that the
suppression of TNAP enzyme activity in Hyp osteocytes was rescued in Hyp/Fgf23Δ/flox/
Col2.3cre+ mice (Fig 7). TNAP activity was similar in osteoblasts at the bone surface in all geno-
types, corroborating the notion that Fgf23 does not contribute to the regulation of TNAP
Fig 6. rFGF23 administration suppresses TnapmRNA expression and increases PPi concentration in WT osteocyte-like cells and bones of WT
mice. (A)mRNA abundance of Ank, Enpp1, and Tnap as well as PPi concentration in cell culture supernatant in WT calvarial osteocyte-like cells
differentiated for 22 d, and subsequently treated with rFGF23 for 24 h. (B)mRNA abundance of Ank, Enpp1, and Tnap in total RNA isolated from whole
femurs and PPi concentration in extracts of whole tibiae from 3-mo-old male WTmice treated with rFGF23 or vehicle for 5 d. Each data point is the
mean ± SD of at least four experimental samples in A, and of at least five mice in B. Individual values are given in S1 Data. *, p < 0.05 versus vehicle.
doi:10.1371/journal.pbio.1002427.g006
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Fig 7. Bone specific deletion of Fgf23 rescues suppressed TNAP activity inHypmice.Histochemical TNAP staining in bone sections fromWT, Hyp,
andHyp/Fgf23Δ/flox/Col2.3cre+mice and quantification of relative fluorescence in osteoblasts and osteocytes. Top panels for each genotype represent
endocortical bone surface, bottom panels cortical bone. Each data point is the mean ± SD of at least four mice. Individual values are given in S1 Data. *,
p < 0.05 versusWT; #, p < 0.05 versusHyp.
doi:10.1371/journal.pbio.1002427.g007
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activity in osteoblasts ofHypmice (Fig 7). In a subset of these mice, we were able to quantify
PPi in distal femurs. Bone PPi concentration was 1.18 ± 0.009 μmol/mg in WT (n = 4),
1.49 ± 0.007 μmol/mg inHyp (n = 2), and 0.91 ± 0.002 μmol/mg in Hyp/Fgf23Δ/flox/Col2.3cre+
mice (n = 2). Collectively, these data suggest that increased Fgf23 secretion is indeed responsi-
ble for the suppression of TNAP expression and subsequent PPi accumulation inHyp bones.
Discussion
In the current study, we identified a novel mechanism contributing to the defective mineraliza-
tion inHypmice. Our data indicate that besides its endocrine role as phosphaturic hormone,
excessive osteocytic Fgf23 secretion has an additional para-/autocrine role in the development
of osteomalacia inHypmice by suppressing TNAP activity in osteocytes, which in turn leads to
accumulation of PPi, a potent inhibitor of mineralization. We hypothesize that the cell-specific
suppression of Tnap in osteocytes but not osteoblasts ofHypmice is based upon the profound
up-regulation of Fgfr3 expression during osteocytic differentiation. This model is shown in Fig
8. Moreover, we demonstrated that conditional deletion of Fgf23 in cells of the osteoblastic
lineage rescued the suppressed TNAP activity in osteocytes ofHypmice in vivo, and that block-
ing of the cell-autonomous increase in Fgf23-FGFR3 signaling inHyp-derived osteocyte-like
cells improved TNAP activity and phosphate production, and decreased PPi concentration in
vitro. However, inhibition of Fgf23 signaling did not fully correct the mineralization defect in
vitro, suggesting that increased local Fgf23 production is only partially responsible for impaired
mineralization inHypmice.
The XLH and Hyp phenotypes are caused by loss-of-function mutations in PHEX/Phex. It
was previously thought that increased ASARM peptides were largely responsible for the cell
autonomous mineralization defect observed in osteoblasts isolated fromHypmice, and par-
tially for the osteomalacia found in Hypmice [18]. Phex binds to and proteolytically cleaves
free ASARM peptides [45,46], and also degrades OPN [21]. ASARM peptides and OPN are
increased in bones of Hypmice [19], and known to impair mineralization in vivo and in vitro
[45,47]. It is interesting to note in this context that transgenic overexpression of PHEX under
different promoters only partially rescued the osteomalacia inHypmice (PHEX-tg/Hyp)
[8,48]. The current study may provide a possible explanation why osteomalacia was not fully
corrected in the majority of studies with PHEX-tg/Hypmice. In this regard, Fgf23 levels
remained significantly higher in Phex-Tg/Hypmice [49], thus TNAP activity may have
remained suppressed in these mice, causing impaired mineralization via PPi accumulation.
An interesting aspect of our study was the striking differences between the expression pro-
files of osteoblasts and osteocytes isolated by sequential digestion from Hyp bones. Whereas
TnapmRNA and protein expression was strongly suppressed in Hyp-derived osteocyte-like
cells, TnapmRNA expression was ~50-fold increased in Hyp relative to WT osteoblast-like
cells. Vice versa, we found increased Fgf23 expression only in osteocytes but not in osteoblasts
ofHypmice as evidenced by sequential digestion of bones. This finding is in agreement with
earlier reports [29,39]. However, LCM-based in situ expression profiling of osteoblasts and
osteocytes revealed increased Fgf23mRNA abundance not only in osteocytes, but also in osteo-
blasts in Hyp bones. Therefore, the relative contribution of osteoblasts and osteocytes to the
increased circulating Fgf23 levels in Hypmice is not entirely clear. Furthermore, in agreement
with earlier studies [39], we found that Fgfr3mRNA abundance is profoundly up-regulated
during osteocytic differentiation especially in Hypmice, supporting the notion that the higher
membrane abundance of FGFR3 in Hyp osteocytes versus osteoblasts forms the basis for the
cell type-specific suppression of Tnap transcription by Fgf23. Collectively, these results under-
score the biological differences between osteocytes and osteoblasts inHypmice and suggest
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that the increased ALP activity in the serum ofHypmice and XLH patients more likely reflects
changes in bone surface cells rather than osteocytes. Although we did not assess TNAP expres-
sion in newly embedded osteocytes at bone-forming surfaces, we speculate that suppression of
TNAP with subsequent accumulation of PPi may also occur in osteoid seams at the bone sur-
face, not only in osteocyte lacunae. Up-regulation of FGFR3 expression in newly embedded
osteocytes may lead to Fgf23-mediated suppression of TNAP, which may in turn result in accu-
mulation of PPi and subsequent inhibition of mineralization in the widened osteoid seams of
Hypmice in addition to increased concentrations of ASARM peptides and OPN.
TNAP, an ectoenzyme, is responsible for the local production of Pi for mineralization via
hydrolyzing PPi in the ECM. Tnap loss-of-function mutants are characterized by impaired
bone mineralization via accumulation of PPi [50]. Furthermore, TNAP-deficient osteoblasts
fail to mineralize in vitro [51], underscoring the pivotal importance of TNAP for bone
Fig 8. Proposedmodel of PPi accumulation through increased Fgf23-FGFR3 signaling in Hyp osteocytes. Fgf23 secreted into the extracellular fluid
binds to FGFR3 and acts as a transcriptional suppressor of Tnap. TNAP is a central molecule in the mineralization process and favors mineralization through
hydrolyzing PPi, thus providing Pi for mineralization. Fgf23 secretion is up-regulated in osteoblasts and especially osteocytes inHyp bones, relative to WT
osteoblasts and osteocytes. FGFR3 expression is reduced inHyp compared with WT osteoblasts. However, differentiation of osteoblasts into osteocytes is
associated with a distinct up-regulation of FGFR3 expression especially inHyp bones. Together with the increased secretion of Fgf23, the upregulation in
FGFR3 leads to autocrine/paracrine suppression of TNAP activity inHyp osteocytes but not osteoblasts, causing accumulation of PPi and inhibition of bone
mineralization in osteocyte lacunae.
doi:10.1371/journal.pbio.1002427.g008
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mineralization. We previously reported that Fgf23-FGFR3 signaling suppresses TNAP tran-
scription and activity, causing PPi accumulation and inhibition of mineralization in vitro [33].
Here, we showed that inhibition of Fgf23-FGFR3 signaling inHyp osteocyte-like cells by treat-
ment with either an FGFR3 inhibitor or an anti-FGF23 antibody improved TNAP activity and
decreased PPi concentration in vitro. In addition, bone-specific deletion of Fgf23 in Hyp/
Fgf23Δ/flox/Col2.3cre+ mice rescued the suppressed TNAP activity in osteocytes of Hypmice.
Although bony PPi concentrations were not quantified after treatment ofHypmice with anti-
Fgf23 antibodies [9] or a pan-FGFR inhibitor [24], it is likely that systemic anti-FGF23 treat-
ment or pan-FGFR inhibition also, at least partially, corrects the increased PPi concentration
in bone. This idea is indirectly supported by our finding that a 5-d treatment of WT mice with
rFGF23 suppressed TNAP expression and increased PPi in bone, suggesting that circulating
FGF23 levels are able to modulate bony PPi metabolism. The latter findings may also have
implications for tumor-induced osteomalacia (TIO), because our data suggest that excessive
extraskeletal production of FGF23 may also lead to PPi accumulation in bone. However, due to
the low affinity of the FGFR3 signaling pathway [33], this mechanism may only become opera-
tive at high circulating FGF23 levels.
Vitamin D hormone levels are inappropriately low inHypmice and in XLH patients due to
the FGF23-mediated suppression of renal 1α-hydroxylase [15]. The vitamin D hormone not
only governs intestinal absorption of calcium and phosphate [52], but also inhibits bone miner-
alization by stimulating the transcription of Enpp1, Ank, and Opn [33,35]. In line with low vita-
min D hormone levels inHypmice, the mRNA abundance of Ank and Enpp1 was almost
undetectable inHyp-derived F-3 osteoblasts. On the contrary, the mRNA abundance of Ank
and Enpp1 was higher inHyp- than WT-derived osteocyte-rich cell fractions ex vivo. There-
fore, inappropriately low vitamin D hormone levels cannot account for the changes observed
in Ank and Enpp1 expression inHyp-derived osteocyte-like cells. Furthermore, inhibition of
Fgf23 signaling partially corrected the increased Ank and Enpp1, but not the increased Opn
mRNA expression, inHyp-derived osteocyte-like cells in our experiments. Collectively, our
data and the work of others suggest that Phex deficiency [39,53], via only partially known sig-
naling pathways at present time, induces a complex pattern of altered gene regulation in which
increased Fgf23 transcription is only a portion of the pathophysiology.
In conclusion, we have found that the mineralization defect in bones ofHypmice and in
cultures ofHyp-derived osteoblasts is not only due to local accumulation of ASARM peptides
and OPN but also due to the Fgf23-driven accumulation of PPi, another potent mineralization
inhibitor. Clearly, more work is required to disentangle the complex interactions between Phex
deficiency, Fgf23 secretion, and para-/autocrine Fgf23 feedback signaling in osteocytes of Hyp
mice. A more complete understanding of these aspects of osteocyte biology may help to design
novel treatments for the mineralization defects observed in diseases associated with excessive
osteocytic Fgf23 secretion such as XLH or chronic kidney disease.
Materials and Methods
Animals
All animal studies were approved by the Ethical Committee of the University of Veterinary
Medicine, Vienna and by the Austrian Federal Ministry of Science and Research and were
undertaken in strict accordance with prevailing guidelines for animal care and welfare (permit
number BMWF-68.205/0037-II/3b/2013). Both WT controls andHypmice were on C57BL/6
background and were kept on normal mouse chow (Ssniff, Soest, Germany). As described [44],
a conditional Fgf23mouse model that harbored alleles with floxed exon 2 was developed
through standard gene targeting. An Fgf23 null allele (Δ) created by mating to the global ella-
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cre transgenic line was bred onto the flox-Fgf23 background to produce Fgf23Δ/flox mice.
Fgf23Δ/flox mice were crossed with type 1 collagen 2.3-kb promoter-cre mice, resulting in
Fgf23Δ/flox/Col2.3cre+ mice by standard mating strategies; this line was mated onto theHyp
genetic background to obtain Hyp/Fgf23Δ/flox/Col2.3cre+ mice [44]. Genotyping of the mice was
performed by multiplex PCR using genomic DNA extracted from the tail. The mice were kept
at 24°C with a 12 h/12 h light/dark cycle and were allowed free access to food and tap water.
All experiments were performed on 3-mo-old males. SomeWTmice received daily intraperito-
neal injections of vehicle (phosphate-buffered saline with 2% DMSO) or 10 μg recombinant
human FGF23 R176/179Q (rFGF23, kindly provided by Amgen, Thousand Oaks, CA) per
mouse for 5 days, and were killed 8–12 hours after the last injection. At necropsy, the mice
were exsanguinated from the abdominal vena cava under anesthesia with ketamine/xylazine
(67/7 mg/kg i.p.) for collection of serum and bones.
Biochemical Analyses
Serum calcium, phosphorus, and ALP activity were analyzed using a Cobas c111 analyzer
(Roche). Intact Fgf23 in serum and culture medium was determined by ELISA (Immutopics).
Isolation of Osteoblast-Rich and Osteocyte-Rich Fractions from Femurs
Primary osteoblast-rich and osteocyte-rich cell fractions were isolated as previously described
[54]. Briefly, both femurs were collected, carefully defleshed, the epiphysis was cut off, and
bone marrow was flushed out using HBSS calcium-free and magnesium-free medium (Life
Technologies). Subsequently, the washed femurs were minced into small pieces using scissors
and digested with 1.25 mg/ml type II collagenase (Invitrogen) at 37°C. Cells released after the
first two digestions of 15 min each were discarded. Cells released after the next three consecu-
tive digestions of 20 min each were collected after passing through a 100-μm nylon cell strainer
as Fraction 3 (F-3), Fraction 4 (F-4) and Fraction 5 (F-5), respectively. Digested bones were
washed once, and treated with 4 mM EGTA in HBSS calcium-free and magnesium-free
medium for 20 min at 37°C. Cells released after this treatment were collected, and bones were
again digested using 1.25 mg/ml type II collagenase for 20 min at 37°C. Cells released after this
digestion were collected and combined with the previous fraction and named F-6/7. Thereafter,
bones were again treated with 4 mM EGTA for 20 min and subsequently with 1.25 mg/ml type
II collagenase for 20 min, cells were collected as before, and named F-8/9.
LCM
LCM was performed as described previously [43]. Briefly, distal femurs of 3-mo-old WT and
Hypmice were snap-frozen in liquid nitrogen with OCT compound (Sakura Finetek, Zoeter-
woude, Netherlands). Four-μm-thick cryosections of were cut on a cryotome (Leica Kryostat
1720), using the cryotape method as described [55]. Cryosections were quickly stained with
HistoStain (Arcturus). Osteoblasts and osteocytes (~100–200 cells per sample each) in the can-
cellous bone of the distal femoral metaphysis were dissected based on their typical morphology,
using a Veritas (Arcturus) LCM system.
RNA Isolation and Quantitative Real-Time PCR
Total RNA was isolated directly after collection of the bone cell fractions using Tri-Reagent
(Ambion, Thermo Fisher Scientific) according to the manufacturer's protocol. RNA quantity
was determined using a Nanodrop photometer (Thermo Scientific). For LCM-harvested osteo-
blasts and osteocytes, total RNA was extracted using the SPLIT RNA Extraction Kit (Lexogen),
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and RNA quality was determined by Agilent RNA 6000 Pico Chip (Agilent Technologies).
cDNA synthesis was performed using the High capacity cDNA reverse transcription kit
(Applied Biosystems). Quantitative RT-PCR was performed on a Rotor-Gene 6000 (Corbett
Life Science) using 5X HOT Firepol Evagreen qPCR mix plus (Solis BioDyne). A melting curve
analysis was done for all assays. Primer sequences are available on request. Efficiencies were
examined based on a standard curve. Expression of target genes was normalized to the expres-
sion of the housekeeping gene glyceraldehyde-3-phosphate-dehydrogenase (Gapdh).
Bone Histology
Isolated mouse femurs were fixed in 4% paraformaldehyde at 4°C overnight and were pro-
cessed and embedded in methylmethacrylate as described previously [56]. Midsagittal sections
of the distal femurs were prepared using a HM 355S microtome (Microm, Walldorf, Germany),
and were stained with von Kossa/McNeal [57]. Sections were analyzed using a Zeiss Axioskop
II microscope.
Culture of Osteoblast- and Osteocyte-Like Cells and In Vitro
Experiments
Calvariae were aseptically harvested from 3-d-old mice, minced and incubated with digestion
medium (α-MEMmedium, 2 mg/ml type II collagenase (Invitrogen) and 2% Penicillin-Strep-
tomycin) at 37°C in a water bath for 4 h. Bone fragments were washed with PBS and cultured
in α-MEMmedium supplemented with 2% Penicillin-Streptomycin and 10% calf serum
(PAA). A similar protocol was followed using femora of 3-d-old mice to obtain femural osteo-
blast cultures. After 90% confluence, cells were grown in the presence of osteoblastic differenti-
ation medium (50 μg/ml ascorbic acid and 10 mM β-glycerophosphate) for 12–22 d as
specified. The differentiated cells were treated with various concentrations of recombinant
human FGF23 carrying the R176/179Q stabilizing mutations (rFGF23, kindly provided by
Amgen Inc., Thousand Oaks, CA, US) for 24 h, 20 ng/ml rat anti-FGF23 antibody (kindly pro-
vided by Amgen Inc., Thousand Oaks, CA, US), or 25 nM FGFR3 inhibitor PD173074 (Sigma)
for 24 or 96 h. At the various time points following treatment, cell culture supernatant and
samples for RNA isolation were collected and stored at −80°C. For BCIP/NBT staining, cells
were fixed using acetone and methanol (30:70) for 5 min at −20°C, and stained using TNM
buffer (100 mM Tris-HCl, pH 9.5, 100 mMNaCl, 5 mMMgCl2) containing 0.175 mg/mL
3-bromo-4-chloro-3-indolyl phosphate (BCIP, Sigma) and 0.45 ng/mL nitrotetrazolium blue
chloride (NBT, Sigma) for 45 min at room temperature. Stained cells were photographed using
a stereomicroscope (Stemi SV6; Zeiss), and the percent area of positive staining was measured
using Image J software.
Histochemistry and Immunohistochemistry
For immunohistochemistry, 5-μm-thick undecalcified sections were obtained from plastic-
embedded femurs as described [56]. Sections were deplastified, incubated for 15 min in 3%
hydrogen peroxide in PBS to block endogenous peroxidase activity, and, after blocking with
10% rabbit serum, incubated with rabbit anti-OPN antibody (Abcam, 1:300) at 4°C overnight.
After washing, sections were incubated for 2 h with biotinylated goat anti-rabbit secondary
antibody (1:2,000, Vector). Finally, the sections were counterstained with Mayer's hematoxylin.
Negative control was performed by omitting the primary antibody. For TNAP staining, deplas-
tified bone sections were incubated with vector red ALP staining kit (Vector Laboratories)
according to the manufacturer's protocol. Fluorescent images of TNAP and DAPI were
obtained using appropriate filter sets. Fluorescence measurements were obtained using Image J
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software as described previously [58]. Fluorescence along the bone surface was marked manu-
ally and quantified using Image J for obtaining relative fluorescence of osteoblasts. At least 15
osteocytes per image and a total of 6 images per animal were chosen for the quantification of
relative fluorescence in osteocytes. Relative fluorescence in osteocytes was normalized to cell
number. The sections were analyzed using a Zeiss Axioskop 2 microscope.
Protein Isolation from Bone
Proteins from femurs were isolated using a previously described protocol [59]. Briefly, femurs
were carefully defleshed and bone marrow was flushed out. After demineralization (300 μl of
1.2 M HCl at 4°C overnight), proteins were isolated using 6M guanidine-HCL in 100 mM Tris
buffer, pH 7.4, at 4°C for 72 h. Extracted proteins were concentrated using ethanol precipita-
tion and re-dissolved in 8M urea buffer. Protein concentration was determined using a BCA
assay (Thermo Scientific).
Western Blotting
Proteins were solubilized in Laemmli sample buffer, fractionated on SDS–PAGE (50 μg/well),
and transferred to a nitrocellulose membrane (Thermo Scientific). Immunoblots were incu-
bated overnight at 4°C with polyclonal rabbit anti‐OPN (1:2,000, Abcam), polyclonal goat
anti-TNAP (1:2,000, R&D Systems) and monoclonal mouse anti-β-actin (1:5,000, Sigma) in
2% (w/v) bovine serum albumin (BSA, Sigma) in a TBS‐T buffer [150 mMNaCl, 10 mM Tris
(pH 7.4/HCl), 0.2% (v/v) Tween-20]. After washing, membranes were incubated with horse-
radish peroxidase-conjugated secondary antibodies (Sigma). Specific signal was visualized by
ECL kit (Amersham Life Sciences). The protein bands were quantified by Image Quant 5.0
software (Molecular Dynamics).
Quantification of PPi Levels
PPi was extracted from whole femurs with 1.2 M HCl at 4°C overnight. HCl was evaporated at
99°C, and samples were resuspended in deionized water. The amount of PPi extracted from
bone or in cell culture supernatant was quantified using the PPiLight Inorganic Pyrophosphate
Assay (LONZA) according to the manufacturer's protocol. Sodium PPi tetrabasic decahydrate
(Sigma) was used as standard.
Statistical Analysis
Statistics were computed using PASW Statistics 17.0 (SPSS Inc., Chicago, IL, US). The data
were analyzed by two-sided t test (two groups) or one-way analysis of variance (ANOVA) fol-
lowed by Student-Newman-Keuls multiple comparison test (>2 groups). p-Values of less than
0.05 were considered significant. Data represent mean values ± SD.
Supporting Information
S1 Data. Data used for making graphs for “Excessive osteocytic Fgf23 secretion contributes
to pyrophosphate accumulation and mineralization defect inHypmice.”
(XLSX)
S1 Fig. Osteocyte-like cells isolated from femurs of newbornHypmice show decreased
TnapmRNA expression and diminished TNAP activity in vitro. (A)mRNA abundance of
the osteoblast-specific gene Ocn and of the osteocyte-specific gene Sost in femoral cells isolated
from newborn WT andHypmice and differentiated for 12 (differentiated osteoblasts, D12) or
22 d (osteocyte-like cells, D22). (B)mRNA abundance of Tnap, Fgf23, and concentration of
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inorganic phosphate in cell culture supernatant, and (C) BCIP/NBT staining in femoral cells
isolated from newborn WT and Hypmice and differentiated for 12 d or 22 d. Each data point
is the mean ± SD of four experimental samples. Individual values are given in S1 Data. ,
p< 0.05 versus D12 in A, , p< 0.05 versus WT.
(TIF)
S2 Fig. Suppression of TnapmRNA expression by rFGF23 in calvarial and femoral osteo-
blasts and osteocyte-like cells isolated fromWT andHypmice. (A–B) Effects of rFGF23
treatment for 24 h in calvarial (A) and femoral (B) osteoblast-like cells (differentiated for 12 d,
D12) and osteocyte-like cells (differentiated for 22 d, D22) isolated from newborn WT and
Hypmice. Each data point is the mean ± SD of triplicates from three different animals. Individ-
ual values are given in S1 Data. , p< 0.05 versus vehicle.
(TIF)
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